Targeting the EWS–FLI1 transcription factor in Ewing sarcoma

[1] Moore DD(2014)Ewing’s sarcoma of bone Cancer Treat Res 162 93-115

[2] Haydon RC(1992)Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours Nature 359 162-165

[3] Delattre O(2005)Oncogene-targeted antisense oligonucleotides for the treatment of Ewing sarcoma Expert Opin Ther Targets 9 825-830

[4] Zucman J(2014)Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy Expert Opin Ther Targets 18 1315-1328

[5] Plougastel B(2009)Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem Nat Prod Rep 26 322-337

[6] Desmaze C(2010)A review of trabectedin (ET-743): a unique mechanism of action Mol Cancer Ther 9 2157-2163

[7] Melot T(2014)Trabectedin, a drug acting on both cancer cells and the tumour microenvironment Br J Cancer 111 646-650

[8] Peter M(2001)Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action Eur J Cancer 37 97-105

[9] Kovar H(2001)Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair Nat Med 7 961-966

[10] Joubert I(2007)Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743 Proc Natl Acad Sci U S A 104 13062-13067

[1] Moore DD(2014)Ewing’s sarcoma of bone Cancer Treat Res 162 93-115

[2] Haydon RC(1992)Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours Nature 359 162-165

[3] Delattre O(2005)Oncogene-targeted antisense oligonucleotides for the treatment of Ewing sarcoma Expert Opin Ther Targets 9 825-830

[4] Zucman J(2014)Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy Expert Opin Ther Targets 18 1315-1328

[5] Plougastel B(2009)Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem Nat Prod Rep 26 322-337

[6] Desmaze C(2010)A review of trabectedin (ET-743): a unique mechanism of action Mol Cancer Ther 9 2157-2163

[7] Melot T(2014)Trabectedin, a drug acting on both cancer cells and the tumour microenvironment Br J Cancer 111 646-650

[8] Peter M(2001)Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action Eur J Cancer 37 97-105

[9] Kovar H(2001)Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair Nat Med 7 961-966

[10] Joubert I(2007)Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743 Proc Natl Acad Sci U S A 104 13062-13067